← 治験一覧に戻る
ホモ接合性家族性高コレステロール血症患者におけるエビナクマブの長期安全性と有効性を評価する
基本情報
- NCT ID
- NCT03409744
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 116
- 治験依頼者名
- Regeneron Pharmaceuticals
概要
The primary objectives of the study are: * To evaluate the long-term safety and tolerability of evinacumab in patients with Homozygous Familial Hypercholesterolemia (HoFH) * To evaluate the long-term safety and tolerability of evinacumab in adolescent patients with HoFH The secondary objectives of the study are: * To evaluate the effect of evinacumab on lipid parameters in patients with HoFH * To evaluate the effect of evinacumab on lipid parameters in adolescent patients with HoFH * To evaluate the potential development of anti-evinacumab antibodies
対象疾患
Homozygous Familial Hypercholesterolemia
介入
evinacumab(DRUG)
依頼者(Sponsor)
Regeneron(INDUSTRY)